Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:5
  • preuzimanja u poslednjih 30 dana:2
članak: 1 od 157  
Back povratak na rezultate
Acta medica Medianae
2020, vol. 59, br. 2, str. 125-131
jezik rada: engleski
vrsta rada: prikaz slučaja
objavljeno: 02/09/2020
doi: 10.5633/amm.2020.0218
Creative Commons License 4.0
Bolesnici sa različitim metastatskim malignitetima i akutnim infarktom miokarda sa elevacijom ST segmenta tretirani primarnom perkutanom koronarnom intervencijom
aKlinički centar Niš, Klinika za kardiovaskularne bolesti + Univerzitet u Nišu, Medicinski fakultet
bKlinički centar Niš, Klinika za kardiovaskularne bolesti
cUniverzitet u Beogradu, Medicinski fakultet + Klinički centar Srbije, Klinika za kardiologiju, Beograd
dUniverzitet u Nišu, Medicinski fakultet

e-adresa: sonja.salinger@gmail.com

Sažetak

Kardiovaskularne bolesti i maligniteti predstavljaju, i dalje, najčešće potencijalne uzroke smrtnog ishoda. Ove bolesti vrlo često koegzistiraju u starijoj populaciji i proizilaze iz istih faktora rizika, kao što je konzumiranje duvana. Napredak u tretmanu maligniteta produžava životni vek, ali isto tako hemioterapija i radioterapija mogu dovesti do raznih oštećenja na nivou organizma. Primena mnogih hemoterapeutika udružena je sa razvojem angine pektoris i infarkta miokarda, dok je radioterapija udružena sa razvojem koronarne bolesti, preko direktnog oštećenja endotela. Pored toga, protrombotski i inflamatorni status u malignim bolestima podstiču razvoj aterosklerotskih plakova i formiranje tromba u koronarnim arterijama. U ovom radu prezentovali smo dva bolesnika sa različitim metastatskim malignitetima i akutnim infarktom miokarda sa ST elevacijom, koji su bili lečeni primarnom perkutanom koronarnom intervencijom (pPCI) i imali različite kratkoročne kliničke ishode.

Ključne reči

Reference

Blann, A.D., Dunmore, S. (2011) Arterial and venous thrombosis in cancer patients. Cardiology Research and Practice, 2011: 1-11, 394740
Cheng, Y., Wu, R., Cheng, M.J., Du, J., Hu, X., Yu, L., Zhao, X., Yao, Y., Long, Q., Zhu, L., Zhu, J., Huang, N., Liu, H., Hu, Y.W., Wan, F. (2017) Carboplatin-induced hematotoxicity among patients with non-small cell lung cancer: Analysis on clinical adverse events and drug-gene interactions. Oncotarget, 8(19): 32228-32236
Coussens, L.M., Werb, Z. (2002) Inflammation and cancer. Nature, 420(6917): 860-867
Demetri, G.D., von Mehren, M., Jones, R.L., Leigh, H.M., Schuetze, S., Staddon, A.P., Milhem, M.M., Elias, A.D., Ganjoo, K.N., Tawbi, H.A., van Tine, B.A., Spira, A.I. (2015) A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS). u: American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, 2015, Abstract 10503
Eisai Inc. (2016) Halaven package insert. Woodcliff Lake, NJ, October, accessed: 1.11. 2018
Feldman, D.R., Schaffer, W.L., Steingart, R.M. (2012) Late cardiovascular toxicity following chemotherapy for germ cell tumors. Journal of the National Comprehensive Cancer Network, 10(4): 537-544
Iliescu, C., Tsitlakidou, D., Giza, D.E., Marmagkiolis, K. (2017) Primary percutaneous coronary interventions in cancer patients. Cancer Research Frontiers, 3(1): 64-71
Iliescu, C.A., Grines, C.L., Herrmann, J., Yang, E.H., Cilingiroglu, M., Charitakis, K., Hakeem, A., Toutouzas, K., Leesar, M.A., Marmagkiolis, K. (2016) SCAI expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiología In. Catheterization and Cardiovascular Interventions, 87(5): 895-899
Ito, D., Shiraishi, J., Nakamura, T., Maruyama, N., Iwamura, Y., Hashimoto, S., Kimura, M., Matsui, A., Yokoi, H., Arihara, M., Irie, H., Hyogo, M., Shima, T., Kohno, Y., Matsumuro, A. (2012) Primary percutaneous coronary intervention and intravascular ultrasound imaging for coronary thrombosis after cisplatin-based chemotherapy. Heart and Vessels, 27(6): 634-638
Jafri, M., Protheroe, A. (2008) Cisplatin-associated thrombosis. Anti-Cancer Drugs, 19(9): 927-929
Jones, R.L., Fisher, C., Al-Muderis, O., Judson, I.R. (2005) Differential sensitivity of liposarcoma subtypes to chemotherapy. European Journal of Cancer, 41(18): 2853-2860
Karabay, K.O., Yildiz, O., Aytekin, V. (2014) Multiple coronary thrombi with cisplatin. J Invasive Cardiol, 26: E18-E20
Khakoo, A.Y., Yeh, E.T.H. (2008) Therapy Insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nature Clinical Practice Oncology, 5(11): 655-667
Krone, R.J. (2010) Managing coronary artery disease in the cancer patient. Progress in Cardiovascular Diseases, 53(2): 149-156
Libby, P. (2002) Inflammation in atherosclerosis. Nature, 420(6917): 868-874
Mateva, S.A., Nikolova, M.R., Valkov, A.V., Nikolova, M.R. (2016) Well-differentiated liposarcoma of the larynx: A case report and review of literature. Journal of Biomedical and Clinical Research, 9(1): 85-89
Nathan, S., Rao, S.V. (2012) Radial versus femoral access for percutaneous coronary intervention: Implications for vascular complications and bleeding. Current Cardiology Reports, 14(4): 502-509
Shah, K., Gupta, S., Ghosh, J., Bajpai, J., Maheshwari, A. (2012) Acute non-ST elevation myocardial infarction following paclitaxel administration for ovarian carcinoma: A case report and review of literature. J Cancer Res Ther, 8:442-4
Togna, G.I., Togna, A.R., Franconi, M., Caprino, L. (2000) Cisplatin triggers platelet activation. Thrombosis Research, 99(5): 503-509
van Leuven, S.I., Franssen, R., Kastelein, J.J., Levi, M., Stroes, E.S.G., Tak, P.P. (2008) Systemic inflammation as a risk factor for atherothrombosis. Rheumatology, 47(1): 3-7
Velders, M.A., Boden, H., Hofma, S.H., Osanto, S., van der Hoeven, B.L., Heestermans, A.A.C.M., Cannegieter, S.C., Jukema, J. W., Umans, V.A.W.M., Schalij, M.J., van Boven, A.J. (2013) Outcome after ST elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention. American Journal of Cardiology, 112(12): 1867-1872
Xu, J., Lupu, F., Esmon, C.T. (2010) Inflammation, innate immunity and blood coagulation. Hämostaseologie, 30(01): 5-9
Yusuf, S.W., Cipolla, C., Durand, J., Lenihan, D.J. (2011) Cancer and cardiovascular disease. Cardiology Research and Practice, 2011: 1-1, 943748
Zamorano, J.L., Lancellotti, P., Rodriguez, M.D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D.J., Lip, G.Y.H., Lyon, A.R., Lopez, F.T., Mohty, D., Piepoli, M.F. (2016) ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Heart Journal, 37(36): 2768-2801
Zöller, B., Ji, J., Sundquist, J.J., Sundquist, K.J. (2012) Risk of coronary heart disease in patients with cancer: A nationwide follow-up study from Sweden. European Journal of Cancer, 48(1): 121-128